Exhibit 99.1



Description automatically generated


Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates


AUSTIN, Texas (November 10, 2022) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended September 30, 2022 and recent updates.


First Quarter Fiscal Year 2023 and Subsequent Highlights:


Announced positive interim data for ANEB-001 from Part B of its Phase 2 clinical trial for Acute Cannabinoid Intoxication in September, 2022


Announced $6.6 million private placement financing in September, 2022


Announced the appointment of Nat Calloway, Ph.D. to Board of Directors


Company Executives are scheduled to participate in the following investor conferences:
Benchmark Discovery Conference, December 1, 2022
J.P. Morgan 41st Annual Healthcare Conference 2023, January 9-12, 2023
BIO CEO and Investor Conference, February 6-9, 2023


Management Commentary


“We remain very pleased that Part B of our ongoing Phase 2 clinical trial is progressing on schedule and we look forward to announcing additional results in the near future,” stated Simon Allen, Chief Executive Officer of Anebulo. “Preparations are ongoing for an observational study in ACI subjects in the emergency department setting to further support the PK/PD model and ANEB-001 development.”





Financial Results for the three months ended September 30, 2022


  Operating expenses in the first quarter of fiscal 2023 were $2.6 million compared with $1.6 million in the same period in fiscal 2022.
  Net loss in the first quarter of fiscal 2023 was $2.6 million, or $(0.11) per share, compared with a net loss of $1.6 million, or $(0.07) per share, in the first quarter of fiscal 2022.
  Cash burn in the first quarter of fiscal 2023 was $2.0 million.
  Cash was $19.2 million as of September 30, 2022.


About Anebulo Pharmaceuticals, Inc.


Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.


Forward-Looking Statements


This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, along with terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Anebulo Pharmaceuticals and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including risks attendant to developing, testing and commercializing the company’s product candidates, and those described in Anebulo Pharmaceutical’s most recent annual report on Form 10-K and in other periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.




Anebulo Pharmaceuticals, Inc.


Scott Anderson

Head of Investor Relations and Public Relations

(858) 229-7063



Rex Merchant

Chief Financial Officer

(512) 598-0931






Condensed Balance Sheet Data


   September 30,   June 30, 
   2022   2022 
Cash  $19,213,697   $14,548,471 
Total assets   19,815,365    15,579,431 
Total liabilities   698,179    512,531 
Total stockholders’ equity   19,117,186    15,066,900 


Condensed Statements of Operations


   Three Months Ended September 30, 
   2022   2021 
Research and development  $1,223,776   $715,098 
General and administrative   1,388,271    839,826 
Total operating expenses   2,612,047    1,554,924 
Loss from operations   (2,612,047)   (1,554,924)
Other income, net   212    1,529 
Net loss  $(2,611,835)  $(1,553,395)
Weighted average common shares outstanding, basic and diluted   23,416,495    23,344,567 
Net loss per share, basic and diluted  $(0.11)  $(0.07)